SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Wollscheid Bernd)
 

Search: WFRF:(Wollscheid Bernd) > Leukocyte different...

Leukocyte differentiation by histidine-rich glycoprotein/stanniocalcin-2 complex regulates murine glioma growth through modulation of anti-tumor immunity

Roche, Francis P. (author)
Uppsala universitet,Vaskulärbiologi,Science for Life Laboratory, SciLifeLab
Pietilä, Ilkka (author)
Uppsala universitet,Institutionen för medicinsk cellbiologi
Kaito, Hiroshi (author)
Uppsala universitet,Institutionen för immunologi, genetik och patologi
show more...
Sjöström, Elisabet O. (author)
Uppsala universitet,Vaskulärbiologi,Science for Life Laboratory, SciLifeLab
Sobotzki, Nadine (author)
ETH Zürich, Department of Health Sciences and Technology & Institute of Molecular Systems Biology, Zürich, Switzerland
Noguer, Oriol (author)
Uppsala universitet,Institutionen för immunologi, genetik och patologi
Persson Skare, Tor (author)
Uppsala universitet,Vaskulärbiologi
Essand, Magnus (author)
Uppsala universitet,Klinisk immunologi,Science for Life Laboratory, SciLifeLab
Wollscheid, Bernd (author)
ETH Zürich, Department of Health Sciences and Technology & Institute of Molecular Systems Biology, Zürich, Switzerland.
Welsh, Michael, 1957- (author)
Uppsala universitet,Institutionen för medicinsk cellbiologi
Claesson-Welsh, Lena (author)
Uppsala universitet,Science for Life Laboratory, SciLifeLab,Vaskulärbiologi
show less...
 (creator_code:org_t)
2018
2018
English.
In: Molecular Cancer Therapeutics. - 1535-7163 .- 1538-8514. ; 17:9, s. 1961-1972
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • The plasma-protein histidine-rich glycoprotein (HRG) is implicated in phenotypic switching of tumor-associated macrophages, regulating cytokine production and phagocytotic activity, thereby promoting vessel normalization and anti-tumor immune responses. To assess the therapeutic effect of HRG gene delivery on CNS tumors, we used adenovirus-encoded HRG to treat mouse intracranial GL261 glioma. Delivery of Ad5-HRG to the tumor site resulted in a significant reduction in glioma growth, associated with increased vessel perfusion and increased CD45+ leukocyte and CD8+ T cell accumulation in the tumor. Antibody-mediated neutralization of colony-stimulating factor-1 suppressed the effects of HRG on CD45+ and CD8+ infiltration. Using a novel protein interaction-decoding technology, TRICEPS-based ligand receptor capture (LRC), we identified Stanniocalcin-2 (STC2) as an interacting partner of HRG on the surface of inflammatory cells in vitro and co-localization of HRG and STC2 in gliomas. HRG reduced the suppressive effects of STC2 on monocyte CD14+ differentiation and STC2-regulated immune response pathways. In consequence, Ad5-HRG treated gliomas displayed decreased numbers of Interleukin-35+ Treg cells, providing a mechanistic rationale for the reduction in GL261 growth in response to Ad5-HRG delivery. We conclude that HRG suppresses glioma growth by modulating tumor inflammation through monocyte infiltration and differentiation. Moreover, HRG acts to balance the regulatory effects of its partner, STC2, on inflammation and innate and/or acquired immunity. HRG gene delivery therefore offers a potential therapeutic strategy to control anti-tumor immunity.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinsk bioteknologi -- Medicinsk bioteknologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Medical Biotechnology -- Medical Biotechnology (hsv//eng)

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view